In an adult patient without hepatic disease, pregnancy, or contraindicating drug interactions, what is the best selective serotonin reuptake inhibitor (SSRI) for generalized anxiety disorder?

Best SSRI for Anxiety

For an adult with generalized anxiety disorder, sertraline, escitalopram, or paroxetine are the first-line SSRI choices, with escitalopram having a slight edge due to its favorable tolerability profile and lower potential for drug-drug interactions.

Primary Recommendation

SSRIs as a class are first-line pharmacotherapy for generalized anxiety disorder, with meta-analyses demonstrating small to medium effect sizes compared to placebo (SMD -0.55) 1. Among individual agents, escitalopram, sertraline, and paroxetine have the strongest evidence base and are specifically recommended as first-line options 2, 3, 1.

Choosing Between SSRIs

While head-to-head trials show comparable efficacy between SSRIs 4, escitalopram may be preferred for the following reasons:

• Lowest drug interaction potential: Citalopram/escitalopram have the least effect on CYP450 isoenzymes compared with other SSRIs, resulting in lower propensity for drug interactions 5
• Proven efficacy across anxiety disorders: Escitalopram 10-20 mg/day demonstrates efficacy in GAD, panic disorder, social anxiety disorder, and OCD with relapse prevention data showing 4.04 times lower relapse risk versus placebo 6
• Favorable tolerability: Only 7% withdrawal rate due to adverse events, comparable to placebo 6

Alternative First-Line Options

Sertraline is equally appropriate as first-line therapy:

• Comparable efficacy to paroxetine in head-to-head trials (56-57% reduction in HAM-A scores) 4
• Well-established evidence base across anxiety disorders 2, 1
• May require twice-daily dosing at lower doses 5

Paroxetine is also first-line but has important caveats:

• Proven efficacy with 6+ month continuation data 2
• Higher discontinuation syndrome risk due to shorter half-life 5
• Associated with increased suicidal thinking compared to other SSRIs 5
• More drug-drug interactions via CYP2D6 5

Agents to Avoid or Use Cautiously

Fluvoxamine: Greatest potential for drug-drug interactions (affects CYP1A2, CYP2C19, CYP2C9, CYP3A4, and CYP2D6) and higher discontinuation syndrome risk 5

Citalopram: Risk of QT prolongation and Torsade de Pointes at doses >40 mg/day; contraindicated in long QT syndrome 5

Practical Implementation

Starting approach:

• Begin with subtherapeutic "test" dose to assess for initial anxiety/agitation side effect 5
• For escitalopram: start 5-10 mg daily, target 10-20 mg daily
• Increase slowly in smallest increments at 1-2 week intervals for shorter half-life agents (sertraline, escitalopram) 5

Timeline expectations:

• Statistically significant improvement by week 2
• Clinically significant improvement by week 6
• Maximal improvement by week 12 or later 5

Duration of treatment:

• Continue for at least 6 months after achieving remission based on relapse-prevention data 2

Critical Safety Considerations

Absolute contraindications:

• Concurrent MAOI use (risk of serotonin syndrome) 5
• For citalopram: long QT syndrome 5

Monitor for serotonin syndrome when combining with other serotonergic agents (tramadol, triptans, other antidepressants, dextromethorphan, St. John's wort) - especially in first 24-48 hours after dose changes 5

Common early adverse effects (emerge within first few weeks): nausea, diarrhea, headache, insomnia, initial anxiety/agitation 5